Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), got 90% of the distribution channel in the US. 

The company said on Tuesday that it succeeded in listing Zymfentra in all six public and private insurance programs managed by the three largest US pharmacy benefit managers (PBMs).

The PBMs act as intermediaries between pharmacies, drug manufacturers, and insurance companies.

Celltrion’s coverage across all three PBMs marks a significant milestone for the South Korean pharmaceutical industry. It follows SK Biopharm’s epilepsy drug Xcopri, which succeeded in 2021.

Zymfentra, a self-administered version of Celltrion's intravenous biosimilar Remsima, was approved as a new drug in the US last October.

Celltrion forecasts Zymfentra sales to reach 250 billion won ($189 million) this year and expects this to grow to 1 trillion won in 2025 and 2 trillion won in 2026.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com